Molecular Partners AG represents a strong focus on innovation, collaboration, and scientific excellence. The company is dedicated to the development of innovative therapies based on its proprietary DARPin platform. With a commitment to addressing unmet medical needs, Molecular Partners AG strives to partner with leading pharmaceutical companies and advance the discovery and development of novel treatments. The company's corporate philosophy emphasizes a patient-centric approach, aiming to improve the lives of individuals by delivering transformative therapies. By harnessing the power of protein engineering, Molecular Partners AG aims to create breakthrough medicines and make a positive impact on healthcare.

Molecular Partners AG, a leading biotechnology company, is primarily present in several countries and regions worldwide. The company has a prominent presence in Switzerland, as it is based in Zurich. Additionally, Molecular Partners AG has established a strong foothold in Europe, including the European Union member states. Its global presence extends to the United States, with activities and collaborations in the biotech hub of Boston. With an expanding network and growing collaborations, Molecular Partners AG is well-positioned to serve and operate in various countries and regions, enabling it to contribute to the advancement of innovative biopharmaceutical solutions.

Molecular Partners AG has achieved several significant milestones in its journey. The company has successfully advanced its proprietary DARPin platform, leading to strategic partnerships with renowned pharmaceutical companies. With a focus on developing innovative therapeutics, Molecular Partners has witnessed notable achievements, including the initiation of clinical trials for its lead oncology asset, MP0250. The company has also made progress in its ophthalmology pipeline, with the start of clinical studies for its candidate, abicipar. Additionally, Molecular Partners has gained global recognition through collaborations with key industry players, establishing a solid foundation for its continued growth and success.

Molecular Partners AG is a Swiss biotechnology company specializing in the development of innovative therapeutic proteins known as DARPin®s. It was established in 2004 by Christian Zahnd, Michael Stumpp, and Andreas Plückthun. Molecular Partners has a strong scientific foundation in protein engineering and has collaborated with leading pharmaceutical companies globally. The company's DARPin® platform offers advantages over conventional therapeutic approaches, including high specificity, low immunogenicity, and extended half-life. Molecular Partners has a diverse pipeline targeting multiple diseases, including oncology, ophthalmology, and infectious diseases. With a commitment to advancing patient care, Molecular Partners AG continues to leverage its expertise in protein engineering to develop innovative therapies that address unmet medical needs.

The main competitors of Molecular Partners AG in the market are large biopharmaceutical companies such as Roche Holding AG, Novartis AG, and Pfizer Inc. These companies also focus on developing innovative biologic therapies and have a broader range of resources and expertise. However, Molecular Partners AG distinguishes itself by its novel DARPin technology, which provides advantages in terms of specificity, safety, and ease of manufacturing. This unique technology sets Molecular Partners AG apart from its competitors and positions it as a leading player in the biopharmaceutical industry.

Molecular Partners AG is primarily active in the biotechnology and pharmaceutical industries.

The business model of Molecular Partners AG revolves around its innovative biotechnology platform, DARPin®. This platform enables the development of differentiated therapeutic candidates, leveraging the targeted nature and multi-specificity of DARPins®. By pioneering the development of DARPins®, Molecular Partners AG aims to address unmet medical needs and create value for patients, physicians, and partners. Through collaborations, licensing agreements, and partnerships, the company seeks to advance its drug candidates across various therapeutic areas, including oncology, ophthalmology, and immunology. Molecular Partners AG's business model focuses on harnessing the potential of DARPins® to deliver effective and precise treatment options for patients worldwide.

P/E-talet för Molecular Partners är −1,87.

Det Molecular Partners KUV är 21,03.

AlleAktien Qualitätsscore för Molecular Partners är 1/10.

förväntade Molecular Partners omsättningen är 7,48 Mkr. CHF.

förväntade Molecular Partners vinst är −84,19 Mkr. CHF.

Molecular Partners AG is a biotech company specializing in the development of therapeutics with multi-specificity. The company was founded in 2004 and is headquartered in Zurich, Switzerland. The business model of Molecular Partners is based on the development of innovative therapeutics based on the DARPin technology (Designed Ankyrin Repeat Proteins). These are artificially produced proteins that specifically bind to certain target structures in tumor cells or inflammation sites. By using multi-specificity, Molecular Partners' therapeutics are able to address multiple targets simultaneously, leading to improved efficacy and safety. Molecular Partners' portfolio currently includes several drug candidates in various stages of development. The main candidate is MP0250, a multi-specific antibody conjugate (SMAC) for the treatment of solid tumors. MP0250 is currently in Phase II clinical trials and has the potential to become a new standard therapy in oncology. Another important candidate is MP0274, a multi-specific antibody conjugate for the treatment of neovascular eye diseases such as wet AMD. Preliminary results indicate that MP0274 has better efficacy and longer duration of action than the current standard of treatment. In addition, Molecular Partners has partnerships with various pharmaceutical companies, including Amgen, Novartis, and Allergan, to develop innovative therapeutics together. Molecular Partners also collaborates with the biotech company AGC Biologics to improve its production technologies and bring its drug candidates to the market faster and more efficiently. Furthermore, the company also offers services in the field of protein design. It provides its customers with the opportunity to create and produce custom proteins based on the DARPin technology. These services are tailored to the biotech and pharmaceutical sectors and have the potential to generate significant scientific advances and product pipeline developments in national and international customer programs. Molecular Partners' business model is focused on close collaboration with its customers, partners, and stakeholders. The company relies on a stringent, science-based, and agile development strategy aimed at identifying and validating promising drug candidates. In this way, Molecular Partners aims to maintain and expand a strong position in the biotech market in the long term. In summary, Molecular Partners AG is an innovative biopharmaceutical company that has a strong focus on the development of multi-specific antibody conjugates (SMAC). The company relies on a stringent, science-based, and agile development strategy to bring its drug candidates to the market quickly and efficiently. Through collaboration with partners and customers in the national and international arena, as well as the provision of custom proteins, the company aims to sustainably strengthen its position in the biotech industry.

Molecular Partners delar ut en utdelning på 0 CHF fördelad över utbetalningar per år.

Utbytet kan för närvarande inte beräknas för Molecular Partners eller så distribuerar bolaget inget utbyte.

ISIN för Molecular Partners är CH0256379097.

WKN för Molecular Partners är A12DEH.

Ticker-symbolen för Molecular Partners är MOLN.SW.

Under de senaste 12 månaderna betalade Molecular Partners en utdelning på . Detta motsvarar en direktavkastning på ungefär . För de kommande 12 månaderna förväntas Molecular Partners betala en utdelning på 0 CHF.

Aktiens direktavkastning för Molecular Partners är för närvarande .

Molecular Partners betalar ut dividenden kvartalsvis. Denna distribueras under månaderna .

Molecular Partners betalade utdelning varje år under de senaste 0 åren.

För de kommande 12 månaderna förväntas utdelningar uppgå till 0 CHF. Detta motsvarar en utdelningsavkastning på 0 %.

Molecular Partners tilldelas sektorn 'Hälsa'.

För att få den senaste utdelningen från Molecular Partners den 2025-02-02 på 0 CHF var du tvungen att ha aktien i ditt depå innan ex-dagen den 2025-02-02.

Utdelningen av den senaste dividenden skedde den 2025-02-02.

Under år 2024 delade Molecular Partners ut 0 CHF i form av utdelningar.

Utdelningarna från Molecular Partners betalas ut i CHF.